Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, NY, CT, CO, WA, MD, L3 · listed Jun 10, 2010 → Jun 26, 2024
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:58 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
5 of 25 offerings report sales commissions totalling $5,360,759; 1 reports finder's fees totalling $845,624; 1 reports proceeds to related persons totalling $45,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jan 20, 2026 D File 021-570448 | $210,000 | $0 | $0 | H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗ |
| EDGAR ↗ | Jun 26, 2024 D File 021-516941 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 1, 2024 D File 021-509186 | $1,381,852 | $0 | $0 | Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗ RBC Capital Markets, LLC BrokerCheck CRD 31194 ↗ |
| EDGAR ↗ | Oct 10, 2023 D File 021-494182 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2023 D File 021-489348 | $0 | $0 | $45,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 9, 2023 D File 021-483867 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 22, 2022 D File 021-456567 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 10, 2021 D File 021-420647 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 7, 2021 D File 021-412547 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 20, 2021 D File 021-400058 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2020 D File 021-366535 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 20, 2018 D File 021-326260 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 3, 2018 D File 021-322748 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 24, 2018 D File 021-303962 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 28, 2016 D File 021-256143 | $3,168,907 | $0 | $0 | MTS Securities, LLC BrokerCheck CRD 104059 ↗ |
| EDGAR ↗ | Oct 22, 2015 D File 021-249874 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 2, 2015 D File 021-246838 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 24, 2014 D File 021-230835 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 25, 2014 D File 021-228991 | $0 | $845,624 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 30, 2012 D File 021-187690 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jan 13, 2012 D File 021-171877 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 13, 2012 D File 021-171878 | $200,000 (est.) | $0 | $0 | Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗ via Roth Capital Partners, LLC (CRD 15407 ↗) |
| EDGAR ↗ | Jan 28, 2011 D File 021-154520 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 18, 2010 D File 021-143754 | $400,000 (est.) | $0 | $0 | Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗ via Roth Capital Partners, LLC (CRD 15407 ↗) |
| EDGAR ↗ | Jun 10, 2010 D File 021-143283 | $0 | $0 | $0 (est.) | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | BiomX Inc. | Director | Jan 20, 2026 | D | $3,300,000 similar: $1,694,259–$16,000,000 | $3,300,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Elion Therapeutics, Inc. | Director | Jun 26, 2024 | D | $83,835,000 similar: $2,000,000–$19,999,994 | $25,436,790 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | BiomX Inc. | Director | Apr 1, 2024 | D | $61,547,439 similar: $1,694,259–$16,000,000 | $61,547,439 | 34 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Avalyn Pharma Inc. | Director | Oct 10, 2023 | D | $189,182,622 similar: $2,000,000–$19,999,994 | $189,182,622 | 26 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dracen Pharmaceuticals, Inc. | Director | Aug 10, 2023 | D | $2,785,000 similar: $2,000,000–$19,999,994 | $2,285,000 | 6 similar: 2–16 | $2,741 similar: $10,000–$50,000 |
| EDGAR ↗ | Adaptive Phage Therapeutics, Inc. | Director | Jun 9, 2023 | D | $30,000,000 similar: $2,000,000–$19,999,994 | $11,999,999 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Innervace, Inc. | Director | Aug 22, 2022 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $9,999,973 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dracen Pharmaceuticals, Inc. | Director | Nov 10, 2021 | D | $17,046,698 similar: $2,000,000–$19,999,994 | $8,584,398 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARS Pharmaceuticals, Inc. | Director | Sep 7, 2021 | D | $54,999,987 similar: $1,694,259–$16,000,000 | $54,999,987 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Adaptive Phage Therapeutics, Inc. | Director | May 20, 2021 | D | $53,262,037 similar: $2,000,000–$19,999,994 | $23,262,000 | 59 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Avalyn Pharma Inc. | Director | May 8, 2020 | D | $35,695,957 similar: $2,000,000–$19,999,994 | $35,499,998 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Mirum Pharmaceuticals, Inc. | Director | Nov 20, 2018 | D | $120,063,750 similar: $1,694,259–$16,000,000 | $60,063,750 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ARS Pharmaceuticals, Inc. | Director | Oct 3, 2018 | D | $20,000,003 similar: $1,694,259–$16,000,000 | $8,000,002 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dracen Pharmaceuticals, Inc. | Director | Jan 24, 2018 | D | $40,489,688 similar: $2,000,000–$19,999,994 | $8,488,896 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Aprecia Pharmaceuticals Co | Director | Jan 28, 2016 | D | $83,996,852 similar: $1,694,259–$16,000,000 | $78,996,852 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Oct 22, 2015 | D | $64,999,949 similar: $2,000,000–$19,999,994 | $64,999,949 | 27 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Sep 2, 2015 | D | Indefinite similar: $2,000,000–$19,999,994 | $0 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Dec 24, 2014 | D | $42,500,002 similar: $2,000,000–$19,999,994 | $42,500,002 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ALPINE IMMUNE SCIENCES, INC. group: Alpine Immune Sciences | Director | Nov 25, 2014 | D | $40,000,000 similar: $1,694,259–$16,000,000 | $30,000,000 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Rib-X Pharmaceuticals, Inc. | Director | Nov 30, 2012 | D | $67,500,000 similar: $1,694,259–$16,000,000 | $18,686,500 | 4 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Talon Therapeutics, Inc. | Director | Jan 13, 2012 | D | $70,390,800 similar: $2,000,000–$19,999,994 | $10,315,800 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Talon Therapeutics, Inc. | Director | Jan 13, 2012 | D | $2,291,000 similar: $2,000,000–$19,999,994 | $258,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rib-X Pharmaceuticals, Inc. | Director | Jan 28, 2011 | D | $22,000,000 similar: $1,694,259–$16,000,000 | $5,500,000 | 11 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Talon Therapeutics, Inc. | Director | Jun 18, 2010 | D | $97,562,000 similar: $2,000,000–$19,999,994 | $37,512,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Rib-X Pharmaceuticals, Inc. | Director | Jun 10, 2010 | D | $15,000,000 similar: $1,694,259–$16,000,000 | $5,500,000 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Jonathan Leff. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Jonathan Leff appears on a new Form D, or when a court case or SEC action is matched to them. See plans →